Photocatalytic degradation of organic pollutants is an effective way to overcome environmental pollution. During the past few years, carbon materials have demonstrated great potential to improve photocatalytic performance of ZnO nanomaterials. This review will comment on recent developments of carbon materials (including fullerene, carbon nanotube, and graphene) coupling to improve photocatalytic performance of ZnO for photodegradatation of organic pollutants. The effects of carbon materials on enhancing photocatalytic performance of ZnO include enhancing structure stability, increasing amounts of active sites of pollutant adsorption, boosting electron acceptor formation and transport, enhancing photosensitization, narrowing band gap, etc. Moreover, basic mechanisms how carbon materials enhance photocatalytic activity of ZnO materials are discussed according to the interaction between ZnO and carbon materials. Finally, concluding remarks and current challenges are highlighted with perspectives for future developments of ZnO-based carbon photocatalysts. This review aims at recent research advances on ZnO-based carbon photocatalysts developed for photocatalysis of organic contaminant degradation.

Lymph node metastasis is an important aspect for tumor metastasis, which accounts for a majority of cancer death. Non-invasive imaging techniques play a more important role than traditional lymph node biopsy for diagnosis of metastatic lymph nodes. However, non-specific information of lymph node such as size and morphology could only be obtained in traditional imaging techniques, which always bring about mission detection. Thus, lymph-targeted contrast agents are attracting much interest. Presently, most contrast agents are based on the mechanism of passive targeting, which could be affected by the number and function of macrophages in the lymph nodes. Therefore, it is beneficial to study the tumor lymphatic metastases through developing new lymph-targeted contrast agents, which could bring fresh prospect for tumor diagnosis and treatment. The paper reviews the progress of lymph-targeted contrast agents and their diagnosis technology for cancer.